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Synthetic nucleoside mimics with modified nucleobase and/or 
sugar moieties are of considerable importance in the search for 
new structural leads exhibiting biologically interesting activity.1 
Some nucleoside analogues substituted at various positions on the 
heterocycle, are known to have potent biological properties and 
have been investigated, for instance, as antiviral agents (against 
HSV, VZV, CMV, HIV, HBV and HCV), non-radioactive 
fluorescent labels for DNA and as anticancer drugs.2 Extensive 
studies have been carried out on 5-substituted uracil analogues for 
use in cancer and viral chemotherapy, as enzyme inhibitors.3 
Notable among them are 5-fluorouracil (5-FU) and the 
corresponding 2'-deoxyribonucleoside (FdU) which have been 
used in cancer chemotherapy for decades.4 Furthermore, bicyclic 
furo[2,3-d]pyrimidine nucleosides have demonstrated antiviral 
and antileukemic activity which has led to increased interest in 
preparation of corresponding nucleoside analogues.5 Among 
fluorinated pyrimidine nucleoside analogues, 2’-deoxy-2’-fluoro-
5-methyl-1-β-D-arabinofuranosyluracil (FMAU) and other small 
side-chain 5-substituted derivatives are phosphorylated with 
different efficacy by human and other mammalian nucleoside 
kinases including thymidine kinases TK1 and/or TK2; viral 
kinases such as herpes simplex virus type 1 and 2 (HSV1-TK and 
HSV2-TK).6 Thymine derivatives with 6-(1,3-
dihydroxyisobutenyl) and 6-(1,3-dihydroxyisobutyl) side-chain, 
as ligands for HSV1-TK, were developed as leads for gene 
expression imaging by positron emission tomography (PET).7 In 
view of the importance of 5-substituted uracil derivatives in 
cancer chemotherapy8 and as antiviral agents9 we became 
interested in the synthesis of the novel C-5 and/or C-6 substituted 
pyrimidine derivatives.10 
As part of our ongoing research in drug discovery we initiated 
the preparation of 5-alkyl pyrimidine derivatives (36, 8, 9, 11 
and 17), 5,6-dihydrofuro[2,3-d]pyrimidines (7 and 10) and 5-alkyl 
N-methoxymethyl pyrimidine derivatives (1216). Construction 
of the pyrimidine ring was performed using the classical 
intramolecular cyclization of -(1-carbamyliminomethylene)--
butyrolactone (1) with sodium ethoxide to afford 5-(2-
hydroxyethyl)uracil (2) following a literature method.11 Initially, 
the sodium α-hydroxymethylene-γ-butyrolactone was prepared by 
reaction of -butyrolactone and methylformate in dry ether with 
the presence of sodium methoxide, which was subsequently 
reacted with urea to give 2. Transformation of hydroxyl and 
carbonyl functionalities to chlorine was performed using 
phosphoryl chloride affording chlorinated pyrimidine derivative 3 
(Scheme 1).11 The primary hydroxyl group of compound 2 was 
protected to give 5-(2-acetoxyethyl) substituted uracil 4. 
Chlorination of 4 with phosphoryl chloride and N,N-diethylaniline 
yielded 2,4-dichloropyrimidines with 2-acetoxyethyl (5) and 2-
hydroxyethyl (6) side-chain as well as bicyclic 5,6-
dihydrofuro[2,3-d]pyrimidine derivative (7). Methoxylation of 5 
gave desired 2,4-dimethoxypyrimidine (8) with 2-hydroxyethyl 
side-chain in moderate yield. 2-Chloro-4-methoxypyrimidine (9) 
and 2-methoxy-5,6-dihydrofuro[2,3-d]pyrimidine (10) were also 
isolated as minor products. Fluorination of 9 with 
diethylaminosulfur trifluoride (DAST) as the fluorinating reagent 
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afforded 2-chloro-4-methoxypyrimidine 11 with 2-fluoroethyl 
substituent at C-5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Reagents and conditions: (i) NaOMe, ether, HCOOCH3, 
r.t., 24 h; urea, 3M HCl, 4 C, 24 h; (ii) NaOEt, EtOH, reflux, 6 h; 
(iii) POCl3, N,N-diethylaniline, reflux, 1 h; (iv) Ac2O, pyridine, 
reflux, 1 h; (v) POCl3, reflux, 1 h; (vi) NaOMe, reflux, 1 h; (vii) 
DAST, CH2Cl2, -75 C, 0.5 h. 
 
N-Methoxymethylation of 2 was accomplished with 
methoxymethyl chloride (MOMCl) as alkylating reagent and 
potassium carbonate to yield N-1-MOM (12a), N-3-MOM (12b) 
and N,N-1,3-diMOM (12c) 5-(2-hydroxyethyl)pyrimidine 
derivatives in 24 %, 15 % and 3 % yields, respectively (Scheme 
2). To the best of our knowledge there are only a few reports 
describing the N-methoxymethylated pyrimidine derivatives.12  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: (i) K2CO3, DMF, MOMCl, 
-15 C, 0.5 h, r.t., overnight; (ii) DAST, CH2Cl2, -75 C, 0.5 h. 
The fluorine in side-chain of 12a was introduced using DAST 
affording N-MOM pyrimidine derivative 13 containing 2-
fluoroethyl at C-5 position. N-Methoxymethylation of acetylated 
analog 4 also gave N-1-MOM (14a) and N-3-MOM (14b) 
regioisomers as well as N,N-1,3-diMOM (14c) in 22 %, 2 % and 
17 % yields, respectively. We can deduce that N-alkylation of 
uracil with both hydroxyethyl and acetoxyethyl substituents gave 
target N-1-MOM uracil derivatives in rather low yield (~20 %). 
Thus, we applied a more efficient N-methoxymethylation using 
same reaction conditions but starting from 2,4-dimethoxy-5-(2-
hydroxyethyl)uracil (8) to give N-1-MOM (15) in improved yield 
of 46 %. Compounds 16 and 17 with 2-(methoxymethoxy)ethyl 
substituent at C-5 were also isolated as byproducts.  
Compounds 3–17 were evaluated for their cytostatic activities 
against three human malignant tumor cell lines: breast carcinoma 
(MCF-7), colon carcinoma (HCT116), lung carcinoma (H 460) 
and compared to the reference compound 5-fluorouracil. In 
general, compounds 4, 6 and 8–16 showed no inhibitory activity 
on tumor-cell growth up to 100 µM (data not shown). However, 
moderate inhibition of cell growth was obtained with compounds 
5, 7 and to a certain extent 17 (Table 1).  
Table 1. Inhibitory effects of 6-Me-3, 3, 5, 7 and 17 on the 
growth of malignant tumor cell lines 
aIC50: 50 % inhibitory concentration, or compound concentration required 
to inhibit tumor cell proliferation by 50 %. b5-FU: 5- fluorouracil. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50(µM)
a 
Compd HCT116 MCF-7 H 460 
6-Me-313 20.2 87 30.01 
3 0.80.2 101 30.001 
5 2913 305 310.0 
7 1310 456 220.05 
17 7517 >100 >100 
5-FUb 40.8 140.3 30.3 
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While 2,4-dichloropyrimidine (6) with 5-(2-hydroxyethyl) side 
chain did not show any inhibitory effect, its acetylated structural 
analog 5 exhibited cytostatic activity (IC50 ~ 30 µM). Similar 
activity (IC50 ~ 27 µM) was found for bicyclic 2-chloro-5,6-
dihydrofuro[2,3-d]pyrimidine (7). The 2,4-dimethoxypyrimidine 
(17) with 5-(2-(methoxymethoxy)ethyl) side chain showed only 
slight inhibitory effect against colon carcinoma (HCT116). Of all 
compounds tested, 5-(2-chloroethyl)-2,4-dichloropyrimidine (3) 
exerted the most potent antiproliferative activity (in the low 
micromolar range), especially and rather selectively towards 
HCT116 colon cancer cell line (IC50 = 0.8 µM) (Table 1 and 
Figure 1). Similar results showing significant impact of chlorine 
atoms on biological activity were described previously.13 
Interestingly, the increase in the chlorine content also enhanced 
the antiproliferative effects of 2,4-dichloro-6-methylpyrimidine 
structural congener bearing the same 5-(2-chloroethyl)-
substituent.13  
. 
 
 
 
 
 
 
 
Figure 1. Concentration-response profiles for compound 3 tested on tumor 
cell lines in vitro. PG = percentage of growth. 
 
In order to shed more light on the mechanism of action of the 
most active compound 3, we attempted the flow cytometry 
analysis of potential cell cycle perturbations. The compound was 
tested at two concentrations being close or slightly higher than its 
IC50 (1 and 5 μM) on HCT 116 cells (Table 2). Interestingly, the 
results demonstrated that 3 at the higher concentration (5 µM) 
induced strong G2/M phase arrest at both time points, i.e. the 
majority of cells could not progress through mitosis and 
eventually died by apoptosis, as evidenced by accumulation of 
subG1 cells, representing apoptotic cells. Accumulation of cells in 
G2/M phases (a G2/M phase arrest) points to a damage in the cell, 
which occurs during the S phase (DNA replication), or before 
mitosis (aberrant mitotic spindle formation). The G2 checkpoint 
senses unreplicated DNA, generates a signal leading to cell cycle 
arrest and therefore preventing the initiation of M phase before 
completion of S phase. Thus, it is usually triggered by agents that 
induce DNA- or mitotic spindle-damage. Since compound 3 is 
structurally similar to a pyrimidine antagonist 5-FU, this 
mechanism of cell cycle perturbation is quite peculiar. Namely, 
antimetabolite drugs, such as pyrimidine antagonists arrest/delay 
the cell cycle in G1, or early S phase.14 Nevertheless, the 
chloroethyl-substituent in 3, which is present in other known  
 
Table 3. The apparent permeability (Papp) values for 3 and 6-Me-
3 (with and without P-gp inhibitor) 
 
 
 
 
 
a Elacridar (GF120918) as P-gp inhibitor.16 
alkylating agents (such as: nitrogen mustards, or uracil mustard – 
uramustine) might be responsible for alkylation of DNA, thus 
causing a more severe DNA damage, which induces G2/M arrest 
and apoptosis. More detailed analysis of DNA alkylation/cross 
linking/damage ability of 3 is underway. 
Table 2. The effects of compound 3 at 1 and 5 µM on the cell 
cycle distribution of HCT116 cells after the 24- and 48-hour 
treatments 
Treatment 
Percentage of cells (%)a 
SubG1 G1 S G2/M 
24h 
control 1.8 32.5 50.0  17.4 
1 µM 2.5 33.5 48.8 17.2 
5 µM 8.1 7.8 14.6 77.6 
48h 
control 1.5 42.3  31.0 26.6 
1 µM 1.7 41.7 31.5 26.7 
5 µM 8.5 24.6 14.8 60.7 
aThe numbers represent the percentages of cells in respective cell cycle 
phase (G1, S and G2/M), along with the percentage of cells in the subG1 
(dead cells) obtained by flow cytometry. 
Compound 3 and its 6-methylated structural analog (6-Me-3) 
with pronounced cytostatic activities were selected for 
preliminary ADME assays including permeability and P-
glycoprotein (P-gp) substrate assessment, stability in plasma (rat, 
human and mouse), as well as metabolic stability in liver 
microsomes (rat, human and mouse). These properties are 
important for new molecules design and affect their 
bioavailability in a great manner. Permeability assay was 
designed to determine permeability of selected compounds 
through MDCKII-MDR1 cell monolayers, as well as for their 
identification as potential P-gp supstrate.15 MDCKII-MDR1 cells 
are Madin-Darby canine kidney cells with overexpressed MDR1 
(human multidrug resistance 1) gene. This gene encodes an 
integral membrane protein P-gp that functions as ATP-dependant 
efflux pump, which could have a significant influence on 
compounds permeability. Both compounds 3 and 6-Me-3 showed 
to be highly permeable compounds with Papp values above 20.0 
x 10-6 cm/s
 
(Table 3). Besides, efflux ratios did not exceed 2, 
indicating that both compounds are not P-gp substrates. Results of 
plasma stability showed that 6-Me-3 was more stable in all tested 
species comparing to 3 (Table 4). Moreover, this compound 
exhibited significantly higher (4- to 8-fold) half-life values than 
those of 3, suggesting that methyl substituent at C-6 of pyrimidine 
scaffold in 6-Me-3 has impact on plasma stability. On the 
contrary to this, determination of metabolic stability in liver 
microsomes, monitoring exclusively phase I metabolism, showed 
similar metabolic stability of tested compounds. In addition, both 
compounds exhibited higher stability in human and rat 
microsomes than in mouse microsomes. 
Compd 
Papp(AB) (cm/s) Papp(BA) (cm/s) 
 
Efflux 
ratio  
Papp(AB) ( cm/s) Papp(BA) (cm/s) Efflux 
ratio  - elacridara + elacridar 
3 20.8 x 10-6 25.8 x 10-6 1.2 25.6 x 10-6 29.6 x 10-6 1.2 
6-Me-3 35.8 x 10-6 20.9 x 10-6 0.6 21.6 x 10-6 31.1 x 10-6 1.4 
Table 4. Stability of 3 and 6-Me-3 in plasma and liver 
microsomes of various species 
 
Compd 
Plasma stability Microsomal stability 
% remaining (24 h) 
(t1/2 (min)) 
% remaining (60 min) 
(t1/2 (min)) 
Human Rat Mouse Human Rat Mouse 
3 
0    
(153) 
0    
(24) 
0     
(91) 
65  
(104) 
73  
(134) 
33  
(34) 
6-Me-3 
20  
(600) 
3 
(184) 
22 
(478) 
76  
(145) 
74  
(134) 
41   
(46) 
 
In summary, 5-alkyl N-methoxymethyl pyrimidine derivatives 
(12-16) were prepared by intramolecular cyclization reaction of 
α-(1-carbamyliminomethylene)-γ-butyrolactone (1) with sodium 
ethoxide and subsequent chemical transformations of hydroxyl 
and carbonyl functionalities as well as N-methoxymethylation. 
While N-alkylation of uracil with both 5-(2-hydroxyethyl) (2) and 
5-(2-acetoxyethyl) (4) substituents suffered from poor yield, N-
alkylation of 5-(2-hydroxyethyl)-2,4-dimethoxypyrimidine (8) 
gave N-1-methoxymethyl pyrimidine 15 in improved yield. 
Among all evaluated compounds, pyrimidine derivative 3 that 
bears two aromatic and one aliphatic chlorine atoms showed the 
most potent inhibitory activity against malignant tumor cell lines 
tested, particularly against the colon cancer (HCT116) cell line. 
Interestingly, the cell cycle perturbation analysis demonstrated 
severe DNA damage (G2/M arrest) pointing to a potential DNA 
alkylating ability of chloroethyl-substituted pyrimidine 3. 
Furthermore, this compound exhibited favourable in vitro ADME 
properties, i.e. high permeability and good metabolic stability in 
liver microsomes of human and rat. 
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